Why These 5 Stocks Are Rocketing Higher Amid a Tough Monday Market

Next on our list is TrovaGene Inc (NASDAQ:TROV), whose stock is well in the green after the company announced an agreement with FedMed, giving the latter access to TrovaGene’s Precision Care Monitoring (PCM) tests and services. Cantor Fitzgerald reiterated a ‘Buy’ rating and $10.00 price target on the stock following the announcement of the deal. Shares are up by 17% today, and still have greater than 125% upside potential based on Cantor’s price target.

Hedge fund sentiment was steady in TrovaGene Inc (NASDAQ:TROV) during the third quarter, as the number of funds long the stock remained unchanged at six. Roberto Mignone’s Bridger Management was the largest shareholder of those with 3.29 million shares, valued at $18.7 million at the end of September.

Follow Cardiff Oncology Inc. (NASDAQ:CRDF)

Next up, we’ve got Companhia Energetica Minas Gerais (ADR) (NYSE:CIG), which is up by about 13% today, seemingly on no particular news. Investors should notice, however, that the stock has been falling heavily over the past 12 months, having lost more than 63% and is a volatile stock, with a beta of 1.63.

Hedge fund sentiment also remained stayed steady in Companhia Energetica Minas Gerais (ADR) (NYSE:CIG), as the number of funds long the stock remained unchanged at 11 by the end of the third quarter, with those investors amassing around 1.1% of its outstanding stock.

Although analysts at Vetr downgraded Eros International plc (NYSE:EROS)‘s stock to ‘Buy’ from ‘Strong Buy’, with a price target of $9.72, shares of the company have also gained 13% today, pushing them into green territory for the year, up by over 10%.

During the third-quarter, Eros International plc (NYSE:EROS) registered a slight increase in popularity among the funds that we track, with 16 investors holding long positions at the end of September, versus 14 funds at the end of June. Those investors held 8.4% of the Indian film company’s outstanding stock.

Disclosure: None